All News

Here’s a preview of the featured content to watch for this week on Drug Topics®.

Moderna reported an efficacy rate of 94.1% for its COVID-19 vaccine based on the primary efficacy analysis.

A recent study showed “alarming” rates of reported loneliness, anxiety, depression, and substance use in young adults during COVID-19.

Here’s a roundup of this week’s coronavirus-related news.

As coronavirus disease 2019 (COVID-19) cases rise across the country, members of the MJH Life Sciences COVID-19 Coalition shared their perspectives on pandemic containment efforts.

Lumasiran (Oxlumo; Alnylam Pharmaceuticals) is the first drug approved for the treatment of primary hyperoxaluria type 1, a rare genetic disorder.

The new model will test a new way to lower increasing drug prices for patients paying for drugs under Medicare Part B.

One vaccine dosing regimen for AZD1222 showed 90% efficacy, according to investigators at the University of Oxford.

Here’s a preview of the featured content to watch for this week on Drug Topics®.

Results from the NIAID-sponsored ACTT-2 trial showed that COVID-19 patients treated with baricitinib in combination with remdesivir experienced better recovery times and clinical status.

Pfizer and BioNTech expect to produce up to 50 million doses globally in 2020 and up to 1.3 billion doses by the end of 2021.

The Department of Health and Human Services recently released a final rule requiring health insurers to disclose drug pricing and cost-sharing information

Pfizer and BioNTech today announced that their COVID-19 vaccine candidate showed a 95% efficacy rate in the final analysis of its phase 3 study.

Community non-profits receive funding to support health equity, healthcare providers, and rural communities.

Here’s a preview of the featured content to watch for this week on Drug Topics®.

As part of a new partnership with HHS, the nation’s largest pharmacy chains—as well as independents and regional chains—will be administering free coronavirus disease 2019 (COVID-19) vaccines when they are available.

AmerisourceBergen has reached an agreement with the U.S. Centers for Disease Control and Prevention (CDC) to include Good Neighbor Pharmacy and Elevate Provider Network members in the Federal Pharmacy Partnership Strategy for COVID-19 Vaccination.

Independent pharmacists should tune in to this webinar event to learn how Good Neighbor Pharmacy's 4 core value centers can help them optimize their business.

Interim analysis results from a phase 3 clinical trial reported a vaccine efficacy rate above 90% for BNT162b2. The trial is ongoing until it meets its threshold for confirmed COVID-19 cases.

Pharmacies are seeing an increased demand for flu vaccines in the first season that coincides with the coronavirus pandemic.

MJH Life Sciences™ COVID-19 Coalition will be hosting its next live webinar event “Thinking Long-Term: COVID-19’s Clinical Consequences and Mental Health Effects."

Todd Mizeski, Esq, a Partner in Frier Levitt’s Life Sciences, Litigation Department, discusses the case of Rutledge v. Pharmaceutical Care Management Association.

CMS’ new plan will ensure coverage of COVID-19 vaccines with no out-of-pocket costs, while increasing the number of providers that will administer the vaccine.

Kroger Health is offering rapid antibody testing for coronavirus disease 2019 (COVID-19) across all its pharmacies and clinics by the end of November.

Here’s a preview of the featured content to watch for this week on Drug Topics®.

Walmart filed a pre-emptive suit against 2 government agencies that are threatening to sue Walmart over its pharmacists filling opioid prescriptions.

Remdesivir (Veklury; Gilead) is the first and only fully FDA-approved treatment for COVID-19.

The new guidance provides clarification on requirements for pharmacy interns and technicians to administer childhood and COVID-vaccines, as well as COVID-19 tests.